ADHD Supplement Firm Turns Attention To Ingredient Supply After NAD Review
Executive Summary
Vaya marketed Vayarin supplement in the US, but its parent firm, specialty chemicals company Enzymotec, responds to NAD request for substantiation by saying that it changed "its strategy to focus on serving as an ingredient-supplier rather than engaging in the sale of consumer products." Change includes closing Vaya and ceasing Vayarin sales in the US.
You may also be interested in...
Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention
Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
'Enhanced Brain Function' Supplement Sales Only A Memory After NAD Review
Council of Better Business Bureau's industry self-regulation arm says UltraMax Health, after previously not responding to a request for evidence supporting Max Synapse online ad claims, stated in writing that it stopped using the claims and no longer is selling the product.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.